Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. It will be available as a ...

WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...

The rapid-acting insulin should be administered subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm.

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Sanofi-Aventis' Merilog is the first FDA-approved rapid-acting insulin biosimilar. On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and ...

Discover the latest breakthrough in diabetes treatment with Sanofi-Aventis' Merilog, the first FDA-approved rapid-acting insulin biosimilar.

Merilog has been approved as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. The approval is for both a 3 ...